AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20)

BACKGROUND: Loss of PTEN function leads to increased PI3Kβ signaling. AZD8186, a selective PI3Kβ/δ inhibitor, has shown anti-tumor activity in PTEN-deficient preclinical models. This phase 1b/2 study was conducted to determine the safety and efficacy of AZD8186 and paclitaxel combination in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Suh, Koung Jin, Ryu, Min-Hee, Zang, Dae Young, Bae, Woo Kyun, Lee, Hye Seung, Oh, Hyeon Jeong, Kang, Minsu, Kim, Ji-Won, Kim, Bum Jun, Mortimer, Peter G S, Kim, Hee Jung, Lee, Keun-Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485284/
https://www.ncbi.nlm.nih.gov/pubmed/37036671
http://dx.doi.org/10.1093/oncolo/oyad059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485284/
https://www.ncbi.nlm.nih.gov/pubmed/37036671
http://dx.doi.org/10.1093/oncolo/oyad059

Ejemplares similares